Data synthesis: Network Meta Analysis (NMA)
Head to head trials involving two or more interventions are expensive and time-consuming. As such, they primarily serve a regulatory purpose and, where appropriate, are limited to placebo-controlled trials.
However, the ‘which intervention is better?’ question remains.
The NMA is a better approach to use data in the public domain to model expected outcomes from two or more interventions. Recognised by NICE as a valid approach to understand these expected outcomes in the absence of head to head data, Medialis has vast experience in designing and executing these for publication in support of medical objectives.
Medialis Method supports RWE delivery
Medialis is a medical affairs consultancy servicing the pharmaceutical industry. Unlike some other agencies, we are proactive, not reactive or one-dimensional – if you need it, we can do it.Read More
Pharmaceutical industry medical affairs physicians have more influence over customer prescribing than their sales force.
Within a pharma company, the medical department lead all non-promotional activities (shown in red and green) and these results would seem to make a good case for increasing the relative emphasis on medical spend in relation to the promotional one. At the very least, more medical key evidence-generating activities should be carried out that culminate in a publication.
Given the long history pharma has with the sales representative, it may take a while to steer this oil tanker in a new direction. That said, it may just be time to start turning the wheel.
Medialis Medical Plan
Learn how we can ensure that a medical plan is developed with the full engagement of all stakeholders.
Coordinating and collecting feedback in an efficient way to ensure the items included in the plan are agreed by the internal stakeholders can be a challenge.
Our approach involves using a novel group awareness and consensus methodology to generate and agree, the SWOT, Critical Success Factors (CSFs), Aspirational Statement before we go away and design the tactics themselves.
Leverage of data in RWE generation
Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers
Pharmaceutical companies employ a range of prescriber engagement activities, including promotional personal, non-promotional personal and non-personal activities.
Prescribers rated non-personal engagement activities as the most influential on their prescribing habits, followed by non-promotional personal engagement activities and, lastly, promotional personal engagement activities.